Search results
Results from the WOW.Com Content Network
The dose is 5–10 mg/kg and side effects are high blood pressure followed by low blood pressure and ventricular ectopy. Originally introduced in 1959 for the treatment of hypertension. [2] Its use as an antiarrhythmic for ventricular fibrillation was discovered and patented by Marvin Bacaner in 1969 at the University of Minnesota. [3]
Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. [1] Eptifibatide is a cyclic heptapeptide derived from a disintegrin protein ( P22827 ) found in the venom of the southeastern pygmy rattlesnake ( Sistrurus miliarius barbouri ).
Vernakalant was initially developed by Cardiome Pharma, and the intravenous formulation was bought for further development by Merck in April 2009. [5] In September 2012, Merck terminated its agreements with Cardiome and has consequently returned all rights of the drug back to Cardiome, which as of 2018 is known as Correvio Pharma. [citation needed]
Antiarrhythmic agents, also known as cardiac dysrhythmia medications, are a class of drugs that are used to suppress abnormally fast rhythms (tachycardias), such as atrial fibrillation, supraventricular tachycardia and ventricular tachycardia.
Ventricular fibrillation (V-fib or VF) is an abnormal heart rhythm in which the ventricles of the heart quiver. [2] It is due to disorganized electrical activity. [2] Ventricular fibrillation results in cardiac arrest with loss of consciousness and no pulse. [1] This is followed by sudden cardiac death in the absence of treatment. [2]
National Drug Code (NDC) — administered by Food and Drug Administration. [1] Drug Identification Number (DIN) — administered by Health Canada under the Food and Drugs Act; Hong Kong Drug Registration — administered by the Pharmaceutical Service of the Department of Health (Hong Kong) National Pharmaceutical Product Index - South Africa
Disopyramide (INN, trade names Norpace and Rythmodan) is an antiarrhythmic medication used in the treatment of ventricular tachycardia. [2] It is a sodium channel blocker and is classified as a Class 1a anti-arrhythmic agent. [3] [4] Disopyramide has a negative inotropic effect on the ventricular myocardium, significantly decreasing the ...
(Defibrillation uses a therapeutic dose of electric current to the heart at a random moment in the cardiac cycle, and is the most effective resuscitation measure for cardiac arrest associated with ventricular fibrillation and pulseless ventricular tachycardia. [1])